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Abstract
β-cell replacement therapy, available currently as pancreas or islet transplantation, has developed 
without a clear definition of graft functional and clinical outcomes. The International Pancreas and 
Islet Transplant Association and European Pancreas and Islet Transplantation Association held a 
workshop to develop consensus for an International Pancreas and Islet Transplant Association and 
European Pancreas and Islet Transplant Association Statement on the definition of function and 
failure of current and future forms of β-cell replacement therapy. There was consensus that β-cell 
replacement therapy could be considered as a treatment for β-cell failure, regardless of etiology 
and without requiring undetectable C-peptide, accompanied by glycemic instability with either 
problematic hypoglycemia or hyperglycemia. Glycemic control should be assessed at a minimum 
by glycated hemoglobin (HbA1c) and the occurrence of severe hypoglycemia. Optimal β-cell graft 
function is defined by near-normal glycemic control (HbA1c ≤6.5% [48 mmol/mol]) without 
severe hypoglycemia or requirement for insulin or other antihyperglycemic therapy, and with an 
increase over pretransplant measurement of C-peptide. Good β-cell graft function requires HbA1c 
less than 7.0% (53 mmol/mol) without severe hypoglycemia and with a significant (>50%) 
reduction in insulin requirements and restoration of clinically significant C-peptide production. 
Marginal β-cell graft function is defined by failure to achieve HbA1c less than 7.0% (53 mmol/
mol), the occur-rence of any severe hypoglycemia, or less than 50% reduction in insulin 
requirements when there is restoration of clinically significant C-peptide production documented 
by improvement in hypoglycemia awareness/severity, or glycemic variability/lability. A failed β-
cell graft is defined by the absence of any evidence for clinically significant C-peptide production. 
Optimal and good function are considered successful clinical outcomes.
Pancreas and islet transplantation are established approaches for providing β-cell 
replacement therapy in the treatment of diabetes, and stem cell–derived and xenogeneic 
sources of islet cell tissue for transplantation have entered early-phase clinical trials. 
Understanding the therapeutic effectiveness of existing and future forms of β-cell 
replacement therapy is currently limited by the lack of a clear definition of graft functional 
and clinical outcomes. Moreover, glycemic control metrics have been poorly aligned with 
the field of artificial pancreas (AP) development. This limitation was identified as a 
significant barrier to progress in the field of pancreas and islet transplantation at the 
International Pancreas and Islet Transplant Association (IPITA)—The Transplantation 
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Society Opinion Leaders Meeting on the Future of β-Cell Replacement.1,2 As AP systems 
become available that promise to provide improved glycemic control, similar metrics for 
assessing glycemic control are needed to compare effectiveness across β-cell replacement 
and AP approaches. The current lack of clear definitions for clinical success or failure of 
available β-cell replacement therapies and glycemic metrics has impacted acceptance from 
the endocrinology community that has turned attention away from cellular treatment with 
potential to cure diabetes in hopes that a technologic solution may provide acceptable 
glycemic control for most patients. Only with comparable methods of assessment for the 
various approaches to achieving glycemic control available now and in the future can we 
identify those patients most likely to derive benefit from each type of therapy.
To address the lack of standardized outcome definitions for β-cell replacement therapy, 
IPITA joined with the European Pancreas and Islet Transplant Association (EPITA) for a 2-
day workshop on “Defining Outcomes for β-Cell Replacement Therapy in the Treatment of 
Diabetes” in January 2017 in Igls, Austria. The workshop objectives were to develop 
consensus for an IPITA/EPITA statement on the definition of function and failure of current 
and future forms of β-cell replacement therapies, review the metabolic and immuno-logic 
outcome measures used to select patients and assess the efficacy of β-cell replacement 
therapies and guide therapeutic decisions, ensure consistency of definitions for glycemic 
control metrics with the field of AP device development, and build a network of 
collaborators to foster scientific synergy in the clinical investigation of various β-cell 
replacement and artificial insulin delivery approaches to diabetes.
To review relevant information required to formulate a consensus definition for functional 
and clinical outcomes for β-cell replacement therapy, individual sessions were designed with 
specified objectives (Table 1). Historically, success in pancreas transplantation has been 
defined by independence from exogenous insulin, without consideration of the resultant 
degree of glycemic control, whereas in islet transplantation, success has been defined by 
near-normal glycemic control determined by glycated hemoglobin (HbA1c) in the absence of 
severe hypoglycemia. Recently, JDRF International (formerly known as the Juvenile 
Diabetes Research Foundation) led an initiative to identify and define clinically meaningful 
outcomes for patients with type 1 diabetes (T1D) beyond HbA1c, prioritizing standardization 
of outcomes, such as hypoglycemia, hyperglycemia, time in range (based on continuous 
glucose monitoring [CGM]), and diabetic ketoacidosis. This T1D Outcomes Program also 
evaluated patient-reported outcomes (PROs) but existing evidence were not able to support 
the selection of any specific PRO for the assessment of T1D-related care or research.3 The 
T1D research community is also emphasizing the need to assess benefit beyond reduction in 
HbA1c, arguing that even an increase in HbA1c may be acceptable with an AP system if 
previously frequent hypoglycemia was improved.4 With the International Hypoglycemia 
Study Group providing further consensus on definitions of hypoglycemia for clinical trials,5 
the evaluation of hypoglycemia in addition to some average metric of glycemic control, such 
as HbA1c, will be necessary for the selection of patients for and assessment of all forms of 
β-cell replacement and AP therapies, as has already been established for islet 
transplantation.6 Moreover, consistent outcomes definitions are needed for quality assurance 
in the performance assessment of programs offering various forms of β-cell replacement and 
AP therapies.
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INDICATIONS FOR AND APPROACHES TO β-CELL REPLACEMENT 
THERAPY
The principal indications for β-cell replacement therapy have been to treat insulin-dependent 
patients (T1D and insulin-requiring type 2 diabetes [T2D]) with end-stage renal disease or 
experiencing problematic hypoglycemia.7 Success after a pancreas or islet transplant has 
been judged in part by the elimination of insulin requirements; however, discontinuation of 
insulin should not be at the expense of suboptimal glycemic control. A reasonable 
expectation for insulin-independence is the maintenance of nondiabetic levels of glycemic 
control (HbA1c ≤6.5% [48 mmol/mol]) off exogenous insulin or other antihyperglycemic 
therapy.8 Importantly, use of insulin or other antihyperglycemic therapy after pancreas or 
islet transplantation is not synonymous with graft loss or failure, as patients may require low 
doses of exogenous insulin or other glucose lowering agents to maintain glycemic control in 
the nondiabetic range, which is only possible to achieve when a portion of the insulin 
requirement is provided endogenously from a functioning graft.
Such “partial” function of a β-cell replacement therapy has been viewed as successful when 
particular challenges in glycemic control, such as the occurrence of severe hypoglycemia, 
are eliminated after restoration of endogenous insulin secretion. Indeed, patients with 
problematic hypoglycemia, defined by 2 or more episodes per year of severe hypoglycemia 
or as 1 episode in the context of impaired awareness of hypoglycemia, extreme glycemic 
lability, or major fear and maladaptive behavior, should be considered for either pancreas or 
islet transplantation.7 Other patients to consider are those with problematic hyperglycemia, 
defined by the presence of recurrent episodes of diabetic ketoacidosis or severe, rapidly 
progressing secondary complications of diabetes. All patients should have completed a 
structured education program on basal-bolus insulin delivery with flexible dosing of modern 
insulin analogs using pump or multidose injection delivery based on frequent self-
monitoring of blood glucose (SMBG) with or without CGM.
A unifying concept is the consideration of β-cell replacement therapy as treatment for β-cell 
failure, regardless of etiology, when β-cell failure is associated with glycemic instability and 
either problematic hypoglycemia or hyperglycemia despite availability of and adherence to 
optimized medical care. This allows consideration of candidates beyond T1D to include 
some with advanced insulinopenic T2D, or any cause of insulin-deficient diabetes, such as 
cystic fibrosis-related diabetes and other pancreatogenic forms of diabetes (eg, chronic 
pancreatitis or after pancreatectomy). Although it is expected that C-peptide levels in such 
individuals would be low, the importance of assessing C-peptide levels (as well as insulin 
requirements) is to identify elevated levels consistent with insulin resistance that might 
impart stress on a β-cell graft and compromise the potential for benefit from replacement 
therapy. Undetectable levels of C-peptide, although making it easier to attribute 
posttransplant C-peptide to graft function, should not be required. Thus, levels of C-peptide 
should be measured before transplantation to determine posttransplant graft function.
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OUTCOME MEASURES OF GLUCOSE HOMEOSTASIS
Average glycemic control, particularly over the long term, remains best assessed by 
measurement of HbA1c. However, for shorter-term assessment of average glycemia, mean 
glucose can be assessed from frequent SMBG (most valid with 5 times daily monitoring)9 or 
CGM. Average blood or CGM glucose can be used to estimate the HbA1c under situations 
such as marked anemia or use of dapsone10 when the HbA1c is not accurate. Although there 
is interindividual variability in the mean glucose-HbA1c relationship, the relationship within 
an individual is very reproducible and most influenced by the prior month of glycemia.11 
Consistency of average glucose measures depends, however, on the duration of observation 
and becomes most reliable with 14 or more days. The frequency and duration of SMBG and 
CGM are also important for measures of glycemic variability, which are readily assessed 
from the SD of glucose measurements or glucose coefficient of variation (=SD/mean). The 
glucose SD has been validated against clinical assessment of glycemic lability using only 48 
hours of CGM data.12 Glycemic lability incorporates the temporal aspect to glycemic 
variability and may also be assessed by the glycemic lability index (LI) using at least 4 times 
daily SMBG over a 4-week period.13,14 LI has been validated against clinical assessment of 
glycemic lability13 and is highly reproducible over time.14 Glucose time in range, available 
only from CGM and being promoted for shorter-term assessment of AP systems,4 requires 
further study to understand and validate its use.
The most important measure of hypoglycemia is the occurrence of severe hypoglycemia, 
defined as an event associated with loss of consciousness or requiring third party assistance 
for recovery.15 A recent history of experiencing severe hypoglycemia, impaired awareness of 
hypoglycemia, and marked glycemic lability are established risk factors for experiencing 
future severe hypoglycemia. Thus, problematic hypoglycemia has been defined as 2 or more 
episodes per year of severe hypoglycemia or as 1 episode associated with impaired 
awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive 
behavior.7 Impaired awareness of hypoglycemia is assessed by validated questionnaires 
concerning the glucose threshold at which symptom recognition occurs, with the Clarke 
survey assessing thresholds at both 50 and 60 mg/dL (2.8 and 3.3 mmol/L)16 and the Gold 
survey assessing thresholds at an intermediate 54 mg/dL(3.0 mmol/l).17 Both questionnaires 
provide a score up to 7 with a score of 4 or greater, indicating impaired awareness of 
hypoglycemia that is highly correlated, supporting either survey as an appropriate 
assessment tool even if not directly comparable. Although more laborious to collect and 
requiring 4 weeks of prospective diary keeping together with SMBG records, the HYPO 
score also captures hypoglycemia severity by tabulating the frequency and associated 
symptoms of, and assistance required for treating a glucose level less than 54 mg/dL (<3.0 
mmol/L). The HYPO score can be used to identify those with problematic hypoglycemia13 
and is reproducible.14 More practically, the frequency of episodes or percent time with 
glucose less than 54 mg/dL (<3 mmol/L) can be assessed using either SMBG or CGM. The 
International Hypoglycemia Study Group defined a glucose level less than 54 mg/dL (<3 
mmol/L) as sufficiently low to indicate serious, clinically important hypoglycemia that 
should be reported in clinical trials.5
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The goal, then, for glycemic control outcomes of β-cell replacement therapies should be 
attainment of target levels of HbA1c less than 7.0% (53 mmol/mol), and ideally near-normal 
HbA1c ≤6.5% (48 mmol/mol), in the absence of severe hypoglycemia (Table 2). Additional 
goals may be driven by the indication for treatment: impaired awareness of hypoglycemia 
(Clarke or Gold score ≥4) should be resolved (score <4), serious, clinically important 
hypoglycemia (glucose <54 mg/dL [<3 mmol/L]) should be lessened or eliminated; marked 
glycemic variability or lability should be improved. Where CGM data are available, time 
with serious hypoglycemia (glucose <54 mg/dL [<3 mmol/L]), time with any hypoglycemia 
(<70 mg/dl [<3.9 mmol/L]), time on-target (70–140 mg/dL [3.9–7.8 mmol/L]), time in range 
(70–180 mg/dL [3.9–10 mmol/L] or 54–180 mg/dL [3–10 mmol/L]), and time with any 
hyperglycemia (>180 mg/dL [>10 mmol/L]) should be considered and maybe useful for 
making comparisons to AP systems.4 Although safety considerations differ between β-cell 
replacement and AP system approaches, their detailed assessment is critical and qualitative 
assessment of patient satisfaction will need to be part of future treatment comparisons. In 
particular, the complicated patient groups so far treated with pancreas and islet 
transplantation, those with end-stage renal disease or experiencing problematic 
hypoglycemia, have been excluded from clinical trials of AP systems, and may not derive 
similar benefit with AP as trial participants with relatively uncomplicated diabetes. Future 
assessment of AP systems in patients with end-stage renal disease and those with 
problematic hypoglycemia is needed. Furthermore, use of PROs including health-related 
quality of life, diabetes distress, and fear of hypoglycemia requires further attention.18–20
OUTCOME MEASURES OF β-CELL GRAFT FUNCTION AND DEMAND
Both insulin requirements and levels of stimulated C-peptide reflect the contribution of β-
cell replacement therapy to the resultant state of glycemic control, but at the same time are 
dependent on the degree of glycemic control and underlying insulin sensitivity. With 
improvement in glycemic control, and consequently insulin sensitivity,21 after β-cell 
replacement therapy, a reduction in insulin requirements can be attributed to restoration of 
endogenous insulin secretion from the β-cell graft. However, in the absence of meeting 
glycemic control targets, a measured reduction in insulin requirements cannot be attributed 
to the effectiveness of β-cell replacement therapy. Moreover, a patient withdrawn from 
insulin who is not meeting glycemic control targets as defined above should not be 
considered insulin-independent, because insulin therapy would be indicated to achieve 
appropriate glycemic control.
C-peptide levels, when undetectable before treatment, can be used to assess function of a β-
cell graft, but depend on the metabolic demand for secretion (fasted or stimulated, 
underlying insulin sensitivity, and glucose level) and renal clearance. With increasing 
sensitivity of assays for detection of C-peptide, low levels of questionable clinical 
significance are often detected (eg, <0.3 ng/mL [<0.1 nmol/L] fasting or <0.6 ng/mL [<0.2 
nmol/L] postprandial) despite clinical β-cell failure,22 and may be even higher in the 
presence of uremia or subtotal β-cell loss (eg, with cystic fibrosis-related diabetes and 
advanced insulinopenic T2D). Nevertheless, pretransplant testing of C-peptide is critical to 
inform posttransplant monitoring and should be performed fasting together with a 
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concomitant glucose level with or without stimulated measures. Testing of C-peptide should 
be done the same way before as after transplant.
β-cell replacement therapy aims to restore nondiabetic fasting and postprandial glucose 
without hypoglycemia. Oral glucose tolerance can be assessed by a standardized liquid 
nutrient meal containing a reasonable amount of carbohydrate (~50 g) in place of the 
standard 75 g oral glucose tolerance test used for diagnosis of diabetes. The 90-minute 
glucose during the standard mixed-meal tolerance test (MMTT) is highly correlated with the 
120-minute glucose during the oral glucose tolerance test.23 The posttransplant ratio of C-
peptide-to-glucose fasting is predictive of the 90-minute glucose,24 and so may allow for 
more frequent assessment of β-cell graft function, whereas the MMTT may be most useful 
to resolve uncertainty regarding the interpretation of more routine clinical assessment.
The β-score is a composite measure of β-cell graft function that incorporates the HbA1c, 
insulin requirement, fasting glucose, and C-peptide, and so may be calculated during routine 
clinical assessment, although C-peptide assessment may require a stimulation test.25 More 
recently, the β2-score models the same variables but requires only the fasting C-peptide and 
provides a continuous rather than categorical metric.26 The β-score was initially validated 
against the 90-minute glucose derived from the MMTTand has also been shown to relate to 
CGM metrics of mean glucose, glucose variability, time spent with serious, clinically 
important hypoglycemia (<54 mg/dL [3.0 mmol/L]), and time spent with hyperglycemia 
(>180 mg/dL [10 mmol/L]).27 Although helpful for longitudinal monitoring, the β-score 
remains limited by its summative derivation and absence of including a direct measure of 
hypoglycemia. The β2 score may have potential utility as a continuous variable rather than 
the categorical quantification provided by the β score.
The goal, then, for functional outcomes of β-cell replacement therapies should be, at a 
minimum, to achieve a 50% reduction in insulin requirements (and which should be <0.5 
units per kg body weight per day), assuming adequate glycemic control (HbA1c <7.0% [53 
mmol/mol]), that is associated with an increase from pretransplant measures of C-peptide 
(and which should be at least >0.5 ng/mL [>0.17 nmol/L]) interpreted with a concomitant 
glucose level. More accurate assessment of functional β-cell mass requires determination of 
glucose-potentiation of insulin or C-peptide release in response to a nonglucose insulin 
secretagogue, such as arginine or glucagon22,28,29; however, this gold standard testing of β-
cell secretory capacity is not widely available.
OUTCOME MEASURES OF IMMUNOLOGIC MECHANISMS
Although the success of β-cell replacement therapy ultimately depends on the prevention of 
alloimmune rejection and autoimmune recurrence, and which themselves depend on the 
source of tissue for transplantation and whether the initial cause of β-cell failure was type 1 
(autoimmune) diabetes, the assessment of immune markers was not felt directly relevant to 
the definition of outcomes, but rather to the understanding of unsuccessful outcomes or 
declining functional status.
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CONCLUSION
Defining Successful Outcomes
There was consensus that categorizing β-cell graft function would not be synonymous with 
defining the clinical success of a β-cell replacement therapy. A β-cell graft that provides 
some function but without clinical benefit relative to the indication for treatment should be 
considered a failure. On the other hand, a marginal β-cell graft associated with clear 
evidence of improvement in hypoglycemia or glycemic variability/lability even in the 
absence of achieving target glycemic control may be clinically important, but such an 
outcome would not be considered a success in terms of function because the overall 
treatment goals were not accomplished. This is an important distinction from a functionally 
failed β-cell graft, where in the absence of any evidence for clinically significant C-peptide 
production, consideration should be made to abandoning further monitoring and support of 
the failed graft. In particular, continuation of immunosuppression may no longer be 
indicated unless to support another allograft (eg, a transplanted kidney) or to prevent 
possible sensitization to HLA antigens expressed by the β-cell graft in the case that another 
transplant is being considered. Thus, we sought to define the functional status and clinical 
success of a β-cell graft separately, but using the same components of assessment: the 
HbA1c, severe hypoglycemic events, insulin requirements, and C-peptide. We did not define 
a duration required for correction of HbA1c, protection from hypoglycemia, restoration of C-
peptide, or insulin independence because these measures are fluid and should each be 
evaluated together at any time of posttransplant graft functional assessment. Any reported 
change in glycemic control noted by SMBG and/or CGM should prompt such an assessment 
to identify a functionally stressed or declining graft.
We propose that functional and clinical outcomes can be assigned using a 4-tiered system as 
outlined in Table 3. Optimal β-cell graft function is defined by the presence of near-normal 
glycemic control assessed by nondiabetic HbA1c of 6.5% or less (48 mmol/mol), the 
absence of any severe hypoglycemia, the absence of any requirement for exogenous insulin 
or other antihyperglycemic therapy, and documentation of an increase over pretransplant 
measurement of C-peptide. Good β-cell graft function is defined by the presence of on-target 
glycemic control assessed by an HbA1c less than 7.0% (53 mmol/mol), the absence of any 
severe hypoglycemia, a reduction by more than 50% from baseline in insulin requirements 
or the use of noninsulin antihyperglycemic agents, and documentation of an increase over 
pretransplant measurement of C-peptide. Both optimal and good functional outcomes are 
considered successful clinical outcomes. Marginal β-cell graft function is defined by the 
failure to achieve an HbA1c less than 7.0% (53 mmol/mol), the occurrence of any severe 
hypoglycemia, or less than 50% reduction in insulin requirements when there is 
documentation of an increase over pretransplant measurement of C-peptide. If documented 
impairment in hypoglycemia awareness, frequent occurrence or exposure to serious 
hypoglycemia, or marked glycemic variability/lability is convincingly improved, then it may 
be appropriate to consider that the β-cell graft is clinically impactful. In the absence of any 
evidence for a clinical impact, reassessment of the C-peptide status is warranted as clinically 
insignificant levels, even if quantifiably higher than before transplant, should be considered 
β-cell graft failure. Neither a marginal β-cell graft nor a failed β-cell graft is considered 
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clinically successful. Finally, the ultimate success for a β-cell replacement therapy in any 
individual patient requires the functional clinical benefits to outweigh any potential harm 
from the transplantation procedure or adverse effects of any required immunosuppression.
In conclusion, to be deemed successful, β-cell replacement therapies should require an 
HbA1c less than 7.0% (53 mmol/mol) in the absence of severe hypoglycemia associated with 
a significant greater than 50% reduction in insulin requirements and restoration of clinically 
significant C-peptide production (>0.5 ng/mL or >0.17 nmol/L). Baseline assessment of 
hypoglycemia awareness, hypoglycemia severity, and glycemic variability/lability is helpful 
for monitoring whether a marginally functioning graft is continuing to provide any clinical 
impact. This proposed classification of function and clinical outcomes for β-cell replacement 
therapies is a work in progress and should be validated and further refined based on the 
results from implementation in future prospective investigation.
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TABLE 2.
Indications and goals for β-cell replacement therapies expressed in relation to various glycemic control 
measures
Metric Indicationa Goal Ideal
HbA1c, % (mmol/mol)b >7.5–8.0 (58–64) <7.0 (53) ≤6.5 (48)
SH, events per yr 1 or more None None
Clarke or Gold scorec ≥4 <4 0–1
Time <54 mg/dL (3.0 mmol/L), %d ≥5 <1 0
Glucose SD, mg/dL (mmol/L)e ≥40 (2.2) <40 (2.2) NE
Glucose CV, %e ≥30 <30 NE
Time <70 mg/dL (3.9 mmol/l), %f NE <5 <5
Time 70–180 mg/dL (3.9–10 mmol/L), %f NE >70 >90
Time >180 mg/dL (10 mmol/L), %f NE <20–30 <5
a
Typically more than one measure is used to define indications for β-cell replacement therapy and establish a baseline before treatment.
b
Mean glucose should be used to provide an estimate of the HbA1c in the setting of marked anemia or administration of dapsone.10
cUsed to assess impaired awareness of hypoglycemia.16,17
dUsed to assess exposure to serious, clinically important hypoglycemia,5 which can also be defined by frequency of episodes or using the HYPO 
score.13
eUsed to assess glycemic variability,12 which can also be assessed as glycemic lability using the LI.13
fUsed for comparison to AP systems.4
SH, severe hypoglycemia; SD, standard deviation; CV, coefficient of variation = mean/SD; NE, not established.
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